Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.63 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | STK10 | O94804 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.41 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.41 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928819 | 0.87 | CHRNB2 (0.63) | CHRNB2CHRNA7CHRNA4DYRK1AKCNH2 | |
| SCHEMBL929023 | 0.86 | CHRNA7 (0.69) | CHRNB2CHRNA7CHRNA4KCNH2 | |
| SCHEMBL929227 | 0.83 | CHRNB2 (0.67) | CHRNB2CHRNA7CHRNA4KCNH2 | |
| SCHEMBL928224 | 0.80 | CHRNA7 (0.82) | CHRNB2CHRNA7CHRNA4KCNH2 | |
| SCHEMBL929602 | 0.80 | CHRNA7 (0.74) | CHRNB2CHRNA7CHRNA4KCNH2 | |
| SCHEMBL928223 | 0.78 | CHRNA7 (1.00) | CHRNB2CHRNA7CHRNA4KCNH2 | |
| SCHEMBL928578 | 0.77 | CHRNA7 (0.72) | CHRNB2CHRNA7CHRNA4KCNH2 | |
| Cadaverine Tartrate SCHEMBL1801687 | 0.75 | CHRNB2 (0.58) | CHRNB2CHRNA7CHRNA4 | |
| Cadaverine Tartrate SCHEMBL1801685 | 0.75 | CHRNB2 (0.58) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL927479 | 0.75 | CHRNB2 (0.65) | CHRNB2CHRNA7CHRNA4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | claimed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | claimed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | claimed |
| CN-101189233-A | Substituted diazabicycloalkane derivatives as ligands for the alpha 7 nicotinic acetylcholine receptor | ABBOTT LAB (US) | 2008-05-28 | — | — | CN | claimed |
| JP-2007521323-A | — | — | 2007-08-02 | — | — | JP | claimed |
| EP-1664045-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | Abbott Laboratories (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | claimed |
| WO-2005028477-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS | ABBOTT LABORATORIES (US) | 2005-03-31 | — | — | WO | claimed |
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| CN-101189233-A | Substituted diazabicycloalkane derivatives as ligands for the alpha 7 nicotinic acetylcholine receptor | ABBOTT LAB (US) | 2008-05-28 | — | — | CN | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | CHRNB2 7/4885CHRNA7 1/4885CHRNA4 9/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | CHRNB2 6/4885CHRNA7 1/4885CHRNA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.